IPP Bureau
Granules India’s Gagillapur facility completes USFDA inspection with six observations
By IPP Bureau - September 09, 2024
The recent inspection covered both cGMP and PAI processes
Suspected Mpox case under investigation
By IPP Bureau - September 09, 2024
The patient has been isolated in a designated hospital and is currently stable
Briefs: Ami Organics and Dr. Reddy’s Laboratories
By IPP Bureau - September 09, 2024
Ami informs that PMDA Japan has issued Inspection Result Report declaring the Sachin facility as a Good Manufacturing Practices (GMP) compliant.
Ifinatamab Deruxtecan continues to demonstrate promising response rates for lung cancer in Phase 2 Trial
By IPP Bureau - September 09, 2024
Objective response rate of 54.8% seen with Daiichi Sankyo and Merck’s ifinatamab deruxtecan at 12 mg/kg dose in pretreated patients
Lilly and EVA Pharma collaborate to expand access to baricitinib across 49 low- to middle-income countries in Africa
By IPP Bureau - September 09, 2024
Lilly will license certain baricitinib manufacturing know-how to enable EVA Pharma to manufacture and supply treatment for various immunological diseases
Health Ministry approves introduction of new shorter, more efficacious treatment regimen for drug-resistant TB
By IPP Bureau - September 07, 2024
The BPaLM regimen, which consists four-drug combination – Bedaquiline, Pretomanid, Linezolid and Moxifloxacin, has been proven to be safe, more effective and a quicker treatment option than the previous MDR-TB treatment procedure
Aster CMI Hospital and Coal India provide bone marrow transplants
By IPP Bureau - September 07, 2024
Coal India has committed to providing upto Rs. 3 crore to treat thalassaemia and aplastic anaemia patients for a period of 3 years
KIMS Hospitals, Hyderabad expands into Kerala
By IPP Bureau - September 07, 2024
The company has entered into a long-term lease and operations and management agreement with Sree Chand Specialty Hospital, situated in Kannur
Nanoform and Celanese collaborate for biologics delivery through small implants
By IPP Bureau - September 07, 2024
The companies will combine Nanoform’s Biologics platform with the Celanese VitalDose Drug Delivery platform to further optimize controlled release of biologics
Beiersdorf and Macro Biologics announce partnership to develop antimicrobial peptides
By IPP Bureau - September 06, 2024
Multi-year collaboration focuses on development of biodegradable antimicrobial peptides with broad application possibilities in the areas of skin care and healthcare
Amcor appoints Peter Konieczny as CEO
By IPP Bureau - September 06, 2024
Konieczny has served as Interim CEO since April 2024
Sun Pharma and Moebius Medical granted FTD to MM-II for treatment of osteoarthritis knee pain
By IPP Bureau - September 06, 2024
This Fast Track Designation will enable FDA to review MM-II in an expedited manner, is an important milestone in the development of MM-II
National conference on `Universal Access to Health care: Digital Solutions’ at IHC
By IPP Bureau - September 06, 2024
The conference aims to bring various stakeholders and experts in the field of healthcare and digital solutions for ensuring ‘universal access to affordable and quality healthcare’
Experts discuss on AI-driven solutions to improve healthcare
By IPP Bureau - September 06, 2024
Transform healthcare by integrating expertise from AI, clinical sciences, and basic sciences to harness India’s extensive data sets for improving the access to healthcare
Strides receive USFDA approval for Theophylline ER tablets, 300 mg and 450 mg
By IPP Bureau - September 06, 2024
The product is bioequivalent and therapeutically equivalent to the Reference Listed Drug
